Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...
Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...
Recursion Pharmaceuticals Inc has experienced a significant downturn in financial performance, with revenue growth plummeting to -32.98% in Q3 2025 from +30.14% in Q2 2025. Profitability metrics are ...
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, ...
Hosted on MSN
Teachers 'aren't sleeping' due to 'exponential rise' in AI-generated parental complaints
Teachers 'aren’t sleeping' due to an ‘exponential rise’ in AI-generated parental complaints, education leaders have warned. A survey by Teacher Tapp found 61 per cent of heads have noticed the use of ...
Dielectric Layer,Directional Antenna,Entire Frequency Range,Exponential Profile,Free Space,Frequency Band,Frequency Dispersion,GHz Frequency Band,Geodesic,Higher ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback